Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406276 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00406276 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 28 participants.
The verdict
NCT00406276, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.
Interventions
- DRUG Docetaxel
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406276
The ClinicalTrials.gov registry entry for NCT00406276 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00406276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00406276 about?
NCT00406276 is a clinical study titled "Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer". This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.
What is the current status of trial NCT00406276?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2006-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00406276?
The interventions under investigation include: Docetaxel (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00406276?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.